Dr. LoRusso on Personalized Medicine for Melanoma | OncLive

Dr. LoRusso on Personalized Medicine for Melanoma

April 15, 2015

Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.

All the patients on the trial have progressed on immunotherapy and are now in need of additional treatment. Currently, there are no targeted therapies approved by the FDA for this subset of patients.

By using genotyping, individualized treatments are selected for each of theses patient based on their tumor, explains LoRusso. This approach is predicted to be more effective than the standard of care.


x